Antitumour activity of N6-substituted PMEDAP derivatives against T-cell lymphoma

Anticancer Research

Volumn 21, Issue 3 B, 2001, Pages 2057-2064

  Valerianova M ^a   Votruba, I ^a   Holy A ^a   Mandys, V ^a   Otova B ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

PMEDAP derivatives; Rat; Spontaneous lymphoma

Indexed keywords

9 [2 (PHOSPHONOMETHOXY)ETHYL] 2,6 DIAMINOPURINE; 9 [2 (PHOSPHONOMETHOXY)ETHYL] N6 (2 DIMETHYLAMINOETHYL) 2,6 DIAMINOPURINE; ACYCLIC NUCLEOSIDE; UNCLASSIFIED DRUG; 2,6 DIAMINO 9 (2 PHOSPHONOMETHOXYETHYL)PURINE; 9 (2 (PHOSPHONOMETHOXY)ETHYL) N(6) (2 DIMETHYLAMINOETHYL) 2,6 DIAMINOPURINE; 9 (2 (PHOSPHONOMETHOXY)ETHYL) N(6) ALLYL 2,6 DIAMINOPURINE; 9 (2 (PHOSPHONOMETHOXY)ETHYL) N(6) DIMETHYL 2,6 DIAMINOPURINE; 9-(2-(PHOSPHONOMETHOXY)ETHYL)-N(6)-(2-DIMETHYLAMINOETHYL)-2,6-DIAMINOPURINE; 9-(2-(PHOSPHONOMETHOXY)ETHYL)-N(6)-ALLYL-2,6-DIAMINOPURINE; 9-(2-(PHOSPHONOMETHOXY)ETHYL)-N(6)-DIMETHYL-2,6-DIAMINOPURINE; 9-(2-PHOSPHONYLMETHOXYETHYL)-2,6-DIAMINOPURINE; ADENINE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; N(6) CYCLOPROPYL 9 (2 PHOSPHONYLMETHOXYETHYL) 2,6 DIAMINOPURINE; N(6)-CYCLOPROPYL-9-(2-PHOSPHONYLMETHOXYETHYL)-2,6-DIAMINOPURINE; PHOSPHONIC ACID DERIVATIVE; PRODRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; CYTOSTASIS; DRUG EFFICACY; KIDNEY SLICE; MITOSIS RATE; NONHUMAN; PRIORITY JOURNAL; RAT; T CELL LYMPHOMA; ANIMAL; BLOOD CELL COUNT; BONE MARROW CELL; CANCER TRANSPLANTATION; DOSE RESPONSE; FEMALE; KARYOTYPING; LYMPHOMA; MALE; METABOLISM; MITOSIS; SPRAGUE DAWLEY RAT; TIME;

ADENINE; ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD CELL COUNT; BONE MARROW CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; KARYOTYPING; LYMPHOMA; MALE; MITOSIS; NEOPLASM TRANSPLANTATION; PHOSPHONIC ACIDS; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS;

EID: 0034742549     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Antiviral acyclic nucleotide analogues
2. HPMPC (cidofovir), PMEA (adefovir) and related acyclic nucleoside phosphonate analogues: A review of their pharmacology and clinical potential in the treatment of viral infections
3. The cytostatic effects and mechanism of action of antiviral acyclic adenine nucleotide analogs in L1210 mouse leukemia cells
4. Cytostatic effect of 9-(2-phosphonomethoxyethyl) adenine (PMEA). I. Lymphatic leukemia KHP-Lw-I in Lewis rats
5. Cytostatic effect of 9-(2-phosphonomethoxyethyl)adenine (PMEA). II. Lymphoblastic leukemia in Sprague-Dawley rats
6. In vivo antitumour activity of 9-[(2-phosphonylmethoxy)ethyl]guanine and related phosphonate nucleotide analogues
7. Immunomodulatory properties of 9-(2-phosphonomethoxyethyl)adenine (PMEA)
8. Suppression of rat adjuvant arthritis by some acyclic nucleotide analogs
9. Antimitotic and teratogenic effects of acyclic nucleotide analogues 1-(S)-(3-hydroxy-2-phosphonomethoxyethyl)cytosine (HPMPC) and 9-(2-phosphonomethoxyethyl)adenine (PMEA)
10. Phosphorylation of 9-(2-phosphonomethoxyethyl) adenine and 9-(S)-(3-hydroxy-2-phosphonomethoxypropyl)-adenine by AMP(dAMP) kinase from L1210 cells
11. Interaction of guanine phosphonomethoxyalkyl derivatives with GMP kinase isoenzymes
12. Different inhibitory potencies of acyclic phosphonomethoxyalkyl nucleotide analogs toward DNA polymerases alpha, delta and epsilon
13. Incorporation of selected nucleoside phosphonates and anti-human immunodeficiency virus nucleotide analogues into DNA by human DNA polymerases alpha, beta and gamma
14. PMEApp as a substrate toward replicative DNA polymerases α, δ, ε and ε*
15. Acyclic nucleotide analogues suppress growth and induce apoptosis in human leukemia cell lines
16. Nonproteolyzed form of DNA-polymerase ε from T-cell spontaneous lymphoma of Sprague-Dawley inbred rat: Isolation and characterization
17. Cytostatic effect of 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA). III. Rat and mouse carcinomas and sarcomas
18. Genotoxicity of purine acyclic nucleotide analogs
19. Antitumour activity of novel purine acyclic nucleotide analogs PMEA and PMEDAP
20. 9-[2-(Phosphonomethoxy)ethyl]-2,6-diaminopurine (PMEDAP) - A potential drug against hematological malignancies-induces apoptosis
21. Biological characteristics of spontaneous transplantable T-cell lymphomas in inbred Sprague-Dawley/cub rats
22. Anticancer effect of PMEDAP - Monitoring of apoptosis
23. 6-substituted acyclic purine nucleoside phosphonates
24. 6-cyclopropyl-2,6-diaminopurine: A novel prodrug of 9-(2-Phosphonomethoxyethyl)guanine with improved antitumour efficacy and selectivity in choriocarcinoma-bearing rats
25. Mitotic index and cell proliferation kinetics for identification of antineoplastic activity
26. Characterization of T-cell lymphomas in the Prague inbred Sprague-Dawley/cub rat strain - A model of spontaneous hematological malignancy
27. 6-cyclopropyl-PMEDAP: A novel derivative of 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP) with distinct metabolic, anti-proliferative and differentiation-inducing properties
28. 6-cyclopropyl-2,6-diaminopurine (cpr-PMEDAP) as a prodrug of 9-(2-phosphonylmethoxyethyl)guanine (PMEG)
29. Genotoxicity of purine acyclic nucleotide analogs